article thumbnail

AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01

The Pharma Data

AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. About AlgoTherapeutix AlgoTx was founded in 2018 by Stéphane Thiroloix and Olivier Bohuon to develop topical treatments for complex pain and was incubated by Paris Biotech Santé.

article thumbnail

Macrocyclization via Ring-Closing Metathesis in Drug Discovery & Process Chemistry

Drug Hunter

Recent Applications of Ring-Closing Metathesis in Drug Discovery and Development A selection of representative macrocycles in drug discovery where ring-closing metathesis has been applied to their synthesis are shown below, highlighting chemically diverse macrocycles from programs that have reached clinical development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-driven Precision Medicine to Accelerate Clinical Development of HMBD-001 In HER3 Driven Cancers

The Pharma Data

Our highly experienced teams in Singapore and the US span antibody discovery, pharmacology, production and clinical development. Together we aim to accelerate the journey of new drugs from concept to clinical care. 2018; 78: 3645–3658. Mol Cancer Ther. 2020; 19: 490–501. [3] Cancer Res. SOURCE Hummingbird Bioscience.

article thumbnail

PRITELIVIR MESYLATE

New Drug Approvals

Pritelivir (development codes AIC316 or BAY 57-1293 ) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG. 2018 Oct 23;9:2483.

Virus 62
article thumbnail

New avenues for rare disease treatment

Drug Target Review

Prior to this, he led global high throughput medicinal chemistry, natural product and antibody drug conjugate departments across Germany, France, and the US, and has contributed to the advancement of many projects into clinical development across several therapeutic areas. 2018 [cited 2023 Sep 5]. cited 2023 Sep 5].

Disease 113
article thumbnail

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

Professor Hongwei Wang , Vice-President of Tsinghua University and Bayer Endowed Chair 2018, added: “Over the past sixteen years, Tsinghua University and Bayer have forged a trusted and synergistic partnership that has continuously advanced the integration of scientific discovery and pharmaceutical innovation.

article thumbnail

How to Optimize Drug Development by Combining FSO and FSP Models

PPD

In 2018, market utilization of FSO models was at 72%, with usage of FSP models lagging at 28%. Our FSP solutions help biotech and biopharmaceutical companies meet their timelines by delivering the best of the best: hard-to-find, top-tier staff who bring a customer-first, problem-solving mindset to the clinical development services we provide.